Contemporary representations about the treatment of Hodgkin’s lymphoma in children and adolescents. Review

Classical Hodgkin’s lymphoma (HL) in children and adolescents is one of the most well-cured tumors. However, during a long period of follow-up, the death rate from secondary tumors, cerebrovascular diseases and diseases of the cardiovascular system is increased in the reconvalescents. Radiation therapy plays a major role in the occurrence of delayed complications. Modern protocols for the treatment of HL in children and adolescents optimize therapy depending on risk groups and the level of the early response to induction therapy in order to minimize the number of possible side effects.

Nowadays for the most efficient allocation of patients to risk currently there are several risk factors based on clinical, instrumental and laboratory indicators. The leading place in the staging took positron emission tomography. Modern approaches to diagnosis and treatment of HL require a multicenter study with a centralized revision of histological preparations and visualization data to optimize therapy in children and adolescents. 

1. Swerdlow S., Campo E., Lee Harris N. et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC, 2008.

2. Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Statistics Review, 1975– 2013, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

3. Belgaumi A., Al-Kofide A., Joseph N. et al. Hodgkin lymphoma in very young children: Clinical characteristics and outcome of treatment. Leuk Lymphoma 2008;49(5):910– 6. doi: 10.1080/10428190801947492.

4. Clavel J., Steliarova-Foucher E., Berger C., Danon S., Valerianova Z. Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): report from the Automated Cancer Information System project. Eur J Cancer 2006;42(13):2037–49. doi: 10.1016/j.ejca.2006.05.012.

5. Sharp L., Cotton S., Little J. Descriptive epidemiology. In: Epidemiology of childhood cancer. Edited by Little J. Lyon (IARC Scientific Publications No. 149). France: IARC Press, 1999. Pp. 10–66.

6. Parkin D.M., Kramarova E., Draper G.J. et al. International incidence of childhood cancer. International incidence of childhood cancer. IARC Scientific Publication Lyon, 1998; vol. II (144). ISBN-13 (Print Book).

7. Kabickova E., Sumerauer D., Cumlivska E. et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging 2006;33(9):1025–31. doi: 10.1007/s00259-005-0019-9.

8. London K., Cross S., Onikul E., Dalla-Pozza L., Howman-Giles R. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging 2011;38(2):274–84. doi: 10.1007/s00259-010-1619-6.

9. Robertson V.L., Anderson C.S., Keller F.G. et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2011;80(2):324–32. doi: 10.1016/j.ijrobp.2010.02.002.

10. Paulino A.C., Margolin J., Dreyer Z., Teh B.S., Chiang S. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2012;58(6):860–4. doi: 10.1002/pbc.23273.

11. Metwally H., Courbon F., David I. et al. Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin’s disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition. Int J Radiat Oncol Biol Phys 2011;80(3):793–9. doi: 10.1016/j.ijrobp.2010.02.024.

12. Kluge R., Chavdarova L., Hoffmann M. et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma. PLoS One 2016;11(3):e0149072. doi: 10.1371/journal.pone.0149072.

13. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339(21):1506–14. doi: 10.1056/NEJM199811193392104.

14. Mauz-Korholz C., Metzger M.L., Kelly K.M. et al. Pediatric Hodgkin Lymphoma. J Clin Oncol 2015;33(27):2975–85. doi: 10.1200/JCO.2014.59.4853.

15. Smith M.A., Altekruse S.F., Adamson P.C., Reaman G.H., Seibel N.L. Declining childhood and adolescent cancer mortality. Cancer 2014;120(16):2497–506. doi: 10.1002/cncr.28748.

16. Schellong G., Riepenhausen M., Ehlert K. et al.; German Consortium for Hereditary Breast and Ovarian Cancer. Breast cancer in young women after treatment for Hodgkin’s disease during childhood or adolescence--an observational study with up to 33-year follow-up. Dtsch Arztebl Int 2014;111(1–2):3– 9. doi: 10.3238/arztebl.2014.0003.

17. Weinstein H.J., Hudson M.M., Link M.P. Pediatric Lymphomas. Springer, 2007. Pp. 47–48.

18. Castellino S.M., Geiger A.M., Mertens A.C. et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117(6):1806–16. doi: 10.1182/blood-2010-04-278796.

19. Kreuser E.D., Xiros N., Hetzel W.D., Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin’s disease. J Cancer Res Clin Oncol 1987;113(3):260–6. PMID: 3108263.

20. Bramswig J.H., Heimes U., Heiermann E. et al. The effects of different cumulative doses of chemotherapy on testicular function: Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence. Cancer 1990;65(6):1298–302. PMID: 2106384.

21. Gerres L., Bramswig J.H., Schlegel W., Jurgens H., Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin’s disease. Cancer 1998;83(10):2217–22. PMID: 9827728.

22. Biasoli I., Falorio S., Luminari S., Spector N., Federico M. Fertility in female survivors of Hodgkin’s Lymphoma. Rev Bras Hematol Hemoter 2012;34(1):48–53. doi: 10.5581/1516-8484.20120014.

23. Dorffel W., Ruhl U., Luders H. et al. Treatment of children and adolescent with Hodgkin lymphoma without radiotherapy for patients with complete remission after chemotherapy: final results of multinational trial GPOH-HD95. J Clin Oncol 2013;31(12):1562–8. doi: 10.1200/JCO.2012.45.3266.

24. Mauz-Korholz C., Hasenclever D., Dorffel W. et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010;28(23):3680–6. doi: 10.1200/JCO.2009.26.9381.

25. Феоктистов Р.И. Результаты и осложнения химиолучевой терапии лимфомы Ходжкина у детей и подростков. Дис. ... канд. мед. наук. М., 2011. [Feoktistov R.I. Results and complications of chemoradiotherapy of Hodgkin's lymphoma in children and adolescents. Dissert. candidate of medical sciences. M., 2011. (In Russ.)].

26. Engert A., Schiller P., Josting A. et al.; German Hodgkin’s Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003;21(19):3601–8. doi: 10.1200/JCO.2003.03.023.

27. Specht L., Yahalom J., Illidge T. et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89(4):854–62. doi: 10.1016/j.ijrobp.2013.05.005.

28. Girinsky T., van der Maazen R., Specht L. et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79(3):270–7. doi: 10.1016/j.radonc.2006.05.015.

29. Donaldson S.S., Link M.P., Weinstein H.J. et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007;25(3):332–7. doi: 10.1200/JCO.2006.08.4772.

30. Wolden S.L., Chen L., Kelly K.M. et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma--a report from the Children’s Oncology Group. J Clin Oncol 2012;30(26):3174–80. doi: 10.1200/JCO.2011.41.1819.

31. Friedman D.L., Chen L., Wolden S. et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol 2014;32(32):3651–8. doi: 10.1200/JCO.2013.52.5410.

32. Metzger M.L., Weinstein H.J., Hudson M.M. et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 2012;307(24):2609– 16. doi: 10.1001/jama.2012.5847.